Hyaluronic acid-based nano drug delivery systems against cancer stem cells  by Goodarzi, Navid et al.
Journal of Medical Hypotheses and Ideas (2012) 6, 65Available online at www.sciencedirect.com
Journal of Medical Hypotheses and Ideas
journal homepage: www.elsevier.com/locate/jmhiLETTER TO THE EDITORHyaluronic acid-based nano drug delivery systems
against cancer stem cellsDear Sir,
In the recent letter to editor [1] about our hypothesis
regarding the use of hyaluronic acid-based nano drug delivery
systems against human cancer stem cells (CSCs) [2], Wiwaniti-
kit has expressed his concerns about the possible harming of
normal haematopoietic stem cells expressing CD44. Hyalu-
ronic acid has been applied before as a carrier in drug delivery
and it has been shown that structure modiﬁcation with less
than 25% degree of substitution on carboxyl groups does
not affect their uptake by the receptor [3], while higher degrees
of modiﬁcation result in less uptake and/or cytotoxic effects
[4,5]. This point should be taken into consideration when hyal-
uronic acid-based CSC targeting via CD44 marker is applied.
Considering the chance of haematopoietic stem cells to be
harmed by the system, apparently hyaluronan-assisted drug
delivery systems possess the limitation of affecting normal
stem cells such as haematopoietic ones that express CD44 mar-
ker. It is widely accepted that nanomedicines passively target
the tumour cells due to the well-established theory of the en-
hanced permeation and retention (EPR) of nanoparticles in tu-
mours compared to normal cells. Regarding the possible harm
to normal cells, it can be stated that the affected parts of nor-
mal cells will be recovered taking into account their large pop-
ulation and self-renewal properties [6]. Hence, it is supposed
that removal of small population of CSCs will lead to cancer
eradication while damaging normal stem cells would not lead
to signiﬁcant phenotypic adverse reactions.
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